Literature DB >> 22664831

Radiofrequency ablation for colorectal liver metastases: prognostic factors in non-surgical candidates.

Ayumi Hamada1, Koichiro Yamakado, Atsuhiro Nakatsuka, Junji Uraki, Masataka Kashima, Haruyuki Takaki, Takashi Yamanaka, Yasuhiro Inoue, Masato Kusunoki, Kan Takeda.   

Abstract

PURPOSE: To determine prognostic factors in patients with colorectal liver metastases who were not surgical candidates and received liver radiofrequency (RF) ablation.
MATERIALS AND METHODS: RF ablation was done for 141 colorectal liver metastases in 84 patients. There were 63 (75.0 %, 63/84) males and 21 (25.0 %, 21/84) females, with a mean age of 64.6 ± 10.3. The mean maximum tumor diameter was 2.3 ± 1.4 cm (range 0.5-9.0 cm). Extrahepatic metastases were associated at the time of liver RF ablation in 23 patients (27.4 %, 23/84), and 12 (14.3 %, 12/84) had lung metastases considered controllable by planned lung RF ablation. Prognostic factors were evaluated by univariate and multivariate analyses.
RESULTS: There was no procedure-related mortality. The 1-, 3-, and 5-year overall survival rates were 90.6 % (95 %CI, 83.9-97.2 %), 44.9 % (95 %CI, 31.8-57.9 %), and 20.8 % (95 %CI, 7.3-34.3 %), respectively, with a median survival of 34.9 months. The univariate analysis showed that tumor diameter larger than 3 cm, tumor multiplicity, uncontrollable extrahepatic disease, and previous chemotherapy history were significantly worse prognostic factors. The former three factors remained significant for worse prognosis in the multivariate Cox model. Extrahepatic disease was not a prognostic factor when it could be controlled.
CONCLUSION: Tumor size and number, and uncontrollable extrahepatic metastases were significant prognostic factors.

Entities:  

Mesh:

Year:  2012        PMID: 22664831     DOI: 10.1007/s11604-012-0089-0

Source DB:  PubMed          Journal:  Jpn J Radiol        ISSN: 1867-1071            Impact factor:   2.374


  30 in total

1.  Society of Interventional Radiology clinical practice guidelines.

Authors:  David Sacks; Tricia E McClenny; John F Cardella; Curtis A Lewis
Journal:  J Vasc Interv Radiol       Date:  2003-09       Impact factor: 3.464

2.  Detection of colo-rectal liver metastases: prospective comparison of contrast enhanced US, multidetector CT, PET/CT, and 1.5 Tesla MR with extracellular and reticulo-endothelial cell specific contrast agents.

Authors:  Pier Paolo Mainenti; Marcello Mancini; Ciro Mainolfi; Luigi Camera; Simone Maurea; Antonietta Manchia; Michela Tanga; Francesco Persico; Pietro Addeo; Dario D'Antonio; Antonio Speranza; Luigi Bucci; Giovanni Persico; Leonardo Pace; Marco Salvatore
Journal:  Abdom Imaging       Date:  2009-06-27

3.  Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution.

Authors:  Michael G House; Hiromichi Ito; Mithat Gönen; Yuman Fong; Peter J Allen; Ronald P DeMatteo; Murray F Brennan; Leslie H Blumgart; William R Jarnagin; Michael I D'Angelica
Journal:  J Am Coll Surg       Date:  2010-05       Impact factor: 6.113

4.  Liver resection for colorectal metastases.

Authors:  Y Fong; A M Cohen; J G Fortner; W E Enker; A D Turnbull; D G Coit; A M Marrero; M Prasad; L H Blumgart; M F Brennan
Journal:  J Clin Oncol       Date:  1997-03       Impact factor: 44.544

5.  Chemotherapy plus percutaneous radiofrequency ablation in patients with inoperable colorectal liver metastases.

Authors:  Joseph Sgouros; James Cast; Krishna K Garadi; Maria Belechri; David J Breen; John Rt Monson; Anthony Maraveyas
Journal:  World J Gastrointest Oncol       Date:  2011-04-15

6.  Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases.

Authors:  Hyuk Hur; Yong Taek Ko; Byung Soh Min; Kyung Sik Kim; Jin Sub Choi; Seung Kook Sohn; Chang Hwan Cho; Heung Kyu Ko; Jong Tai Lee; Nam Kyu Kim
Journal:  Am J Surg       Date:  2008-09-11       Impact factor: 2.565

7.  Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation.

Authors:  A R Gillams; W R Lees
Journal:  Eur Radiol       Date:  2009-01-10       Impact factor: 5.315

8.  Radiofrequency ablation of colorectal liver metastases: small size favorably predicts technique effectiveness and survival.

Authors:  Andrea Veltri; Paola Sacchetto; Irene Tosetti; Eva Pagano; Cesare Fava; Giovanni Gandini
Journal:  Cardiovasc Intervent Radiol       Date:  2008-05-28       Impact factor: 2.740

9.  Current diagnostic and therapeutic approaches for colorectal cancer liver metastasis.

Authors:  K A Paschos; N Bird
Journal:  Hippokratia       Date:  2008-07       Impact factor: 0.471

10.  Factors influencing the natural history of colorectal liver metastases.

Authors:  R Stangl; A Altendorf-Hofmann; R M Charnley; J Scheele
Journal:  Lancet       Date:  1994-06-04       Impact factor: 79.321

View more
  23 in total

1.  Volumetric 3D assessment of ablation zones after thermal ablation of colorectal liver metastases to improve prediction of local tumor progression.

Authors:  Elena A Kaye; Francois H Cornelis; Elena N Petre; Neelam Tyagi; Waleed Shady; Weiji Shi; Zhigang Zhang; Stephen B Solomon; Constantinos T Sofocleous; Jeremy C Durack
Journal:  Eur Radiol       Date:  2018-11-06       Impact factor: 5.315

Review 2.  Local treatment of oligometastatic disease: current role.

Authors:  Moritz T Winkelmann; Stephan Clasen; Philippe L Pereira; Rüdiger Hoffmann
Journal:  Br J Radiol       Date:  2019-06-06       Impact factor: 3.039

3.  Aggressive and Multidisciplinary Local Approach to Iterative Recurrences of Colorectal Liver Metastases.

Authors:  Luca Viganò; Vittorio Pedicini; Tiziana Comito; Carlo Carnaghi; Guido Costa; Dario Poretti; Ciro Franzese; Nicola Personeni; Daniele Del Fabbro; Lorenza Rimassa; Marta Scorsetti; Armando Santoro; Luigi Solbiati; Guido Torzilli
Journal:  World J Surg       Date:  2018-08       Impact factor: 3.352

4.  Planned Treatment of Advanced Metastatic Disease with Completion Ablation After Hepatic Resection.

Authors:  Bruno C Odisio; Suguru Yamashita; Livia Frota; Steven Y Huang; Scott E Kopetz; Kamran Ahrar; Yun Shin Chun; Thomas A Aloia; Marshall E Hicks; Sanjay Gupta; Jean-Nicolas Vauthey
Journal:  J Gastrointest Surg       Date:  2016-11-23       Impact factor: 3.452

Review 5.  Interventional Oncology Approach to Hepatic Metastases.

Authors:  Cathal O'Leary; Michael C Soulen; Susan Shamimi-Noori
Journal:  Semin Intervent Radiol       Date:  2020-12-11       Impact factor: 1.513

6.  Local tumour progression after percutaneous ablation of colorectal liver metastases according to RAS mutation status.

Authors:  B C Odisio; S Yamashita; S Y Huang; S Harmoush; S E Kopetz; K Ahrar; Y Shin Chun; C Conrad; T A Aloia; S Gupta; M E Hicks; J-N Vauthey
Journal:  Br J Surg       Date:  2017-02-27       Impact factor: 6.939

Review 7.  Metastatic Liver Disease: Indications for Locoregional Therapy and Supporting Data.

Authors:  Susan Shamimi-Noori; Carin F Gonsalves; Colette M Shaw
Journal:  Semin Intervent Radiol       Date:  2017-06-01       Impact factor: 1.513

8.  Percutaneous Radiofrequency Ablation of Colorectal Cancer Liver Metastases: Factors Affecting Outcomes--A 10-year Experience at a Single Center.

Authors:  Waleed Shady; Elena N Petre; Mithat Gonen; Joseph P Erinjeri; Karen T Brown; Anne M Covey; William Alago; Jeremy C Durack; Majid Maybody; Lynn A Brody; Robert H Siegelbaum; Michael I D'Angelica; William R Jarnagin; Stephen B Solomon; Nancy E Kemeny; Constantinos T Sofocleous
Journal:  Radiology       Date:  2015-08-12       Impact factor: 11.105

Review 9.  Evidence-based medical oncology and interventional radiology paradigms for liver-dominant colorectal cancer metastases.

Authors:  Alan Alper Sag; Fatih Selcukbiricik; Nil Molinas Mandel
Journal:  World J Gastroenterol       Date:  2016-03-21       Impact factor: 5.742

Review 10.  RFA of primary and metastatic lung tumors: long-term results.

Authors:  Stefano Giusto Picchi; Giulia Lassandro; Andrea Bianco; Andrea Coppola; Anna Maria Ierardi; Umberto G Rossi; Francesco Lassandro
Journal:  Med Oncol       Date:  2020-03-27       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.